-

Inocras Presents Poster for Breast Cancer at 2024 ASCO Annual Meeting, Showing Transformative Impact of WGS-based HRD Testing

original The poster presented by Inocras at ASCO Annual Meeting (Photo: Inocras)

The poster presented by Inocras at ASCO Annual Meeting (Photo: Inocras)

SAN DIEGO--(BUSINESS WIRE)--Inocras Inc., a leader in whole genome sequencing (WGS) diagnostics and precision medicine, is proud to present groundbreaking research on radiogenomics and homologous recombination deficiency (HRD) in breast cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting.

In collaboration with Samsung Medical Center and St. Mary’s Hospital, Inocras' research study recruited 145 women with invasive breast cancer. Researchers utilized dynamic contrast-enhanced (DCE) breast MRI to explore the relationship between HRD and specific radiomic features.

HRD, a crucial target in breast cancer treatment, involves key genes known as BRCA1 and BRCA2, whose pathogenic mutations are crucial features for selecting poly (ADP-ribose) polymerase inhibitors (PARPi) treatment. Although BRCA1/2 germline mutations are rare (1%-5%), WGS has revealed that up to 22% of breast cancers display HRD-like genomic characteristics. The study utilized a WGS-HRD approach to identify and validate radiomic features with predictive value for HRD, highlighting their potential as non-invasive imaging biomarkers for primary HRD screening1.

“This research underscores the transformative impact of WGS-based HRD testing, allowing for a more comprehensive view of HRD and the development of better evaluation and screening tools,” said Inocras co-founder Jeong Seok Lee.

Combining WGS-powered genomic data with radiomic insights may enhance the accuracy of HRD screening and optimize treatment strategies. This approach has the potential to benefit a wider range of breast cancer patients, extending beyond those with detectable BRCA1/2 germline mutations, and to advance personalized medicine in oncology.

1. Joonoh Lim et al, Advancing cancer MRD monitoring through tumor whole-genome informed, duplex ctDNA sequencing. J Clin Oncol 42, 2024 (suppl 16; abstr e15044) 10.1200/JCO.2024.42.16_suppl.e15044

About Inocras Inc:

Inocras Inc. (formerly Genome Insight, Inc) is a pioneering provider of whole genome sequencing and analytics services for cancer and rare diseases. The company is dedicated to unlocking the potential of whole genomic data to enable precision health for everyone.

Contacts

Sohee Cho / media@inocras.com

Industry:

Inocras Inc.

Release Versions
English

Contacts

Sohee Cho / media@inocras.com

More News From Inocras Inc.

Inocras Unveils New MRDVision™ Data, Demonstrating Industry-leading Sensitivity in Head-to-Head Clinical Study Against Leading MRD NGS Assay

SAN DIEGO--(BUSINESS WIRE)--Today, Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, announced MRDVision, its solution for minimal residual disease (MRD) detection, validated to CLIA standards. The assay, previously available for research use only, is now ready for use in clinical settings, redefining the standard in MRD testing by enabling ultra-sensitive detection of circulating tumor DNA (ctDNA) with a simulated limit of detection (LOD) as low as 1 part per million (ppm)...

Inocras and Center for Data Driven Discovery in Biomedicine Enter Collaborative Research Agreement to Advance Sinonasal Cancer Research

SAN DIEGO--(BUSINESS WIRE)--Today, Inocras announced the signing of a groundbreaking Collaborative Research Agreement with the Center for Data Driven Discovery in Biomedicine (D3b) to advance research into rare sinonasal cancers. Under the agreement, Inocras will conduct Whole Genome Sequencing (WGS) and bioinformatic analysis on rare sinonasal cancer samples provided by D3b. The leadership team at the Center for Data Driven Discovery in Biomedicine (D3b) - Phillip “Jay” Storm, Adam Resnick, an...

Fore Genomics Partners with Inocras to Launch Pediatric Genetic Health Screening and Newborn Sequencing

SAN DIEGO--(BUSINESS WIRE)--Today, Fore Genomics, a leader in pediatric genetic health screening, announced a strategic partnership with Inocras, a leading innovator in whole genome sequencing (WGS) and AI-powered genetic analysis technologies, to enhance Fore’s proprietary pediatric and newborn health screening services. This collaboration marks a significant step towards improving early detection and intervention for a large number of pediatric-onset genetic conditions, with the initial rollo...
Back to Newsroom